Immune cell therapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests an experimental immune cell therapy called iNK for people with advanced solid tumors that no longer respond to standard treatments. The therapy uses natural killer (NK) cells, which are part of your immune system, to target and attack cancer cells. The goal is to see if it is safe and if it can help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- Your cancer must have spread (metastatic) or come back (recurrent) and cannot be removed with surgery or treated with local therapies.
- Standard treatments (like chemotherapy or targeted therapy) have not worked, caused severe side effects, or are not available for your cancer.
- You need to have at least one tumor that can be measured on a scan (CT, MRI, etc.).
- You must be generally active and able to care for yourself (ECOG performance status 0 or 1).
- Your blood tests and organ function (liver, kidneys, blood counts) must be within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using natural killer (NK) cells, a type of immune cell, to fight advanced solid tumors. It may be an option if standard treatments have stopped working or are not available.
This trial tests an experimental treatment called GK01, which uses your own immune cells (called tumor-infiltrating lymphocytes) that have been taken from your tumor, multiplied in a lab, and given back to you. It is for people with advanced solid tumors that have not responded to standard treatments, and aims to see if these cells can shrink your cancer.
This trial tests whether adding special immune cells (iNKT cells and CD8+ T cells) given by IV infusion can help treat advanced cancers. It mainly looks at safety first, and also checks whether the treatment can shrink or control cancer.
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
This study tests an investigational cell therapy (GK01) for people with advanced solid tumors that have grown despite standard treatment or have no standard treatment option. It may help shrink tumors or slow their growth.
This trial tests whether adding a special immune cell called iNK cells after standard chemoradiation can help keep small cell lung cancer from coming back.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.